Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 10/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 6/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | PRKDC | P78527 | 2/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 6/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.34 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.34 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.34 |
| ▸ | NRP1 | O14786 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17819484 | 0.97 | ATM (0.46) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17819958 | 0.91 | ATM (0.46) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17820404 | 0.90 | PIK3C3 (0.48) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17820478 | 0.89 | PIK3C3 (0.50) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17819453 | 0.86 | ATM (0.44) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17821107 | 0.86 | ATM (0.44) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17821035 | 0.85 | ATM (0.49) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17819457 | 0.85 | PIK3C3 (0.48) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17819966 | 0.84 | ATM (0.49) | ATMPIK3C3PIK3CAPRKDCPIK3CB | |
| SCHEMBL17820870 | 0.84 | ATM (0.47) | ATMPIK3C3PIK3CAPRKDCPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| EP-3042900-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | Fujifilm Corporation (JP) | 2016-07-13 | — | — | EP | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | ATM 3209/4885PIK3C3 3047/4885PIK3CA 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.